Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Blueprint Medicines Corporation, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exact Sciences Corporation, Jazz Pharmaceuticals, Inc., Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Takeda Oncology.
Community Practice Connections™: 22nd Annual International Lung Cancer Congress®
Release Date: October 29, 2021
Expiration Date: October 29, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Blueprint Medicines Corporation, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exact Sciences Corporation, Jazz Pharmaceuticals, Inc., Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess biomarkers and testing strategies to optimize selection of therapy in patients with thoracic malignancies
- Describe emerging evidence concerning the management of patients with nonmetastatic lung cancer
- Integrate recent clinical data on single-agent and combination immunotherapeutic approaches to care for patients with advanced thoracic malignancies
- Evaluate recent data sets on targeted and cytotoxic strategies for the management of patients with thoracic malignancies
- Outline optimal and personalized strategies for sequencing therapy utilizing clinical trial evidence, performance status, and tumor characteristics
- Identify approaches to address variances in care for patients with thoracic malignancies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
Faculty
Professor of Medicine Emeritus
Division of Hematology/Oncology
Director of Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA
Disclosures: Grant research support: Amgen, AstraZeneca, Genentech, Merck & Co; Consultant: AstraZeneca (institutional), Eli Lilly and Company, Guardant Health (institutional), Hoffmann-La Roche/Genentech (institutional), lnivata, 10 Biotech (institutional), Merck & Co, Novartis Pharmaceuticals, Oncocyte (institutional).
Head, Simple Structure of Toraco
Pulmonary Medical Oncology
IRCCS National Cancer Institute
Milan, Italy
Disclosures: Grant research support: AIRC, Italian Medicines Agency AIFA; Consultant: AstraZeneca, Roche, Bristol Myers Squibb, Sanofi, Mirati Therapeutics, Daiichi Sankyo, Merck & Co, Pfizer, Lilly, Takeda, Janssen; Speakers bureau: Merck & Co.
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research, Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosures: Grant research support: AstraZeneca, Eli Lilly and Company, Genentech/Hoffmann-La Roche, Merck & Co; Consultant: AbbVie, ARMO Biosciences, AstraZeneca, Bayer Healthcare Pharmaceuticals, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech/Hoffmann-La Roche, Genmab, Gilead Sciences, Halozyme, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar Therapeutics, Neon Therapeutics, NextCure, Novartis Pharmaceuticals, Ocean Biomedical, Oncternal Therapeutics, Pfizer, Refactor Health, Ribon Therapeutics, Sanofi, Seattle Genetics, Shire Pharmaceuticals, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda Pharmaceutical Company, Tesaro, Tocagen, Ventana Medical Systems, WindMIL Therapeutics; Other: Board Member (non-executive/ independent): Immunocore Holdings Limited, Junshi Biosciences
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
Deputy Director, Stanford Cancer Institute
Stanford, CA
Disclosures: Grant research support: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Merck, Novartis, Pharmacyclics, Seagen, Xcovery; Consultant: Paid consultant: AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Helsinn, Mirati, Unpaid consultant: Genentech/Roche, Merck; Other: Steering committee participation/unpaid adviser: Cellworks, Genentech/Roche, Merck, Takeda
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.